Paul Stallman, MD
Ophthalmic Plastic and Reconstructive Surgery · Pismo Beach, CANPI 1336120005
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,605 of the $4,500 with a category attached, or 80.1%. AbbVie accounts for 87.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $1,805 and has fallen 93.8% since, to $112 in 2025.
Across 78 payments — averaging $57.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Galderma Laboratories, L.p.$255
- Amgen$139
- Revance Therapeutics, Inc.$103
- Merz North America, Inc.$40
- Carl Zeiss Meditec AG$19
What the payments were for
- Speaking & faculty fees$3,60580%
- Food & beverage$83419%
- Education$431%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $3,944 |
| Galderma Laboratories, L.p. | 10 | $255 |
| Amgen | 7 | $139 |
| Revance Therapeutics, Inc. | 3 | $103 |
| Merz North America, Inc. | 2 | $40 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$4,500 in reported general payments places this provider in the 70th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 24 | $1,085 |
| ErythromycinErythromycin Base | 74 | $909 |
| Prednisolone Acetate | 37 | $878 |
| ValacyclovirValacyclovir Hcl | 18 | $282 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $136 |
| Tramadol Hcl | 50 | $58 |
| Triazolam | 14 | $44 |
| Promethazine Hcl | 14 | $26 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Pismo Beach
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Charles KimStockton$21K
- Omar OzgurMission Viejo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.